This study reports 
Vancomycin and teicoplanin are glycopeptide antibiotics active against gram-positive bacteria. Teicoplanin interferes with cell wall biosynthesis by inhibiting polymerization of peptidoglycan, a mode of action very similar to that of vancomycin.
Staphylococci and especially coagulase-negative staphylococci are some of the most common infecting organisms in neutropenic patients; many such patients receive teicoplanin or vancomycin as empirical treatment. So far, there have been few observations reported concerning isolation of teicoplanin-resistant coagulase-negative staphylococci from patients treated with glycopeptides. This study reports the activities of teicoplanin and vancomycin against 185 coagulase-negative staphylococcal strains isolated from 80 neutropenic patients during a period of 1 year.
A total of 92 investigations were conducted on 80 patients admitted to the Hematology Department for acute leukemia from May 1988 to June 1989. Sixty-eight patients were investigated once, and twelve were studied twice. Sixty-two patients were hospitalized for induction remission treatment or bone marrow transplantation, and thirty were hospitalized for control of complications during remission. The distribution of patients according to antibiotic treatment was as follows: 37 had received no treatment with glycopeptides during the previous 3 months, 12 It is apparent that differences exist in MICs according to techniques used (2, 7). Bauernfeind and Petermuller (2) found that the MIC for S. epidermidis could be increased by up to 32-fold by using a solid medium, but recently Felmingham et al. (5) showed that MICs determined by a mac- (16) reported cases of teicoplanin-resistant staphylococci isolated from patients treated with glycopeptides. Our results confirm that it is extremely difficult to select for resistance to vancomycin in vitro, whereas the selection of stepwise resistance has been reported for teicoplanin (10, 15) , with high MICs (>256 mg/liter).
In conclusion, this study suggests that teicoplanin is less active in vitro than vancomycin against many coagulasenegative staphylococci and that previous treatment by a glycopeptide may be responsible for the emergence of teicoplanin resistance. For neutropenic patients who present with a coagulase-negative staphylococcal infection and who have previously been treated with a glycopeptide, a clinical study should be performed to determine the in vivo incidence of these results.
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